Home: NFLIS

NFLIS-Drug

1,181,750 drug reports in 2022

Established in 1997, the National Forensic Laboratory Information System (NFLIS) is a program of the Drug Enforcement Administration (DEA), Diversion Control Division. The DEA's NFLIS-Drug data collection systematically collects drug identification results and associated information from drug cases submitted to and analyzed by participating Federal, State, and local forensic laboratories with drug chemistry sections. The 2022 NFLIS-Drug Annual Report showed that a total of 1,181,750 drug reports were identified by State and local forensic laboratories in the United States.
Learn More
NFLIS-TOX

About 28 million toxicology requests were referred to responding toxicology laboratories in 2019

Toxicology laboratories are a vital source for identifying drugs used by the public. Data from toxicology laboratories can serve as an early warning system to alert the public health community and law enforcement of the drugs they may encounter, leading to improved treatment, prevention, and enforcement policies. The addition of toxicology data to NFLIS is vital for helping DEA improve drug scheduling, enhance available drug intelligence, and better engage their public health partners.
Learn More
NFLIS-MEC

Over 700,000 death cases were accepted by medical examiner and coroner offices (MECs) in 2021, with over 100,000 of those being overdose cases.

MECs are an important data resource for identifying drugs that are used by the public and are potentially deadly. NFLIS-MEC will help DEA improve drug scheduling, enhance available drug intelligence, and better engage DEA’s public safety and public health partners.
Learn More

Overview Publications FAQs Contact Us

Join NFLIS

Laboratory workers looking at NFLIS website on a laptop

Forensic Laboratories

Toxicology Laboratories

Medical Examiners and Coroners Offices

DEA Diversion Website Synth-Opioid Network Data Query System Overview NFLIS Substances

NFLIS News

NFLIS-Drug Snapshot (September 2023)

Nine new substances that were reported across the West, Midwest, South, and Northeast between July 1, 2023 and September 30, 2023, are highlighted in this snapshot. Get the snapshot.
NFLIS-Drug Brief: Substances Co-Reported with Fentanyl in NFLIS-Drug and DEA-Tox, January 2013-June 2023
- Fentanyl has been one of the top five drugs reported to NFLIS-Drug every year since 2017.
- From January to June 2023, 26% of items reported to contain fentanyl also contained at least one co-reported substance.
- In recent years, heroin, xylazine, and fentanyl-related compounds have been the substances most frequently co-reported with fentanyl.
Get the report.
2022 Medical Examiner and Coroner Survey Report

During calendar year 2021, 1,440,580 death cases were referred to the 1,606 medical examiner and coroner offices responding the NFLIS-MEC survey. Get the report.
NFLIS-Drug 2022 Annual Report

From 2021 to 2022, national reports of fentanyl, cocaine, fluorofentanyl, and psilocin/psilocybin increased significantly, while national reports of methamphetamine, cannabis/THC, heroin, alprazolam, and buprenorphine decreased significantly.

Get the report.
NFLIS-DRUG 2022 Midyear Report

At the national level, fluorofentanyl reports nearly doubled from 6,509 reports in the first half of 2021 to 12,174 reports in the first half of 2022. Get the report.
2022 Synth-Opioids Annual Report

The NFLIS DEA Synth-Opioids welcomed 184 new members and 28 forum topics in 2022. Get the report.
2021 Toxicology Laboratory Survey Report

Among responding toxicology laboratories, 48% used a reference laboratory, 29% served as a reference laboratory, and 23% responded that they did not use or serve as a reference laboratory for toxicology testing. Get the report.
NFLIS-Drug Special Report: Gabapentin and Pregabalin Reported in NFLIS, 2011–2020

Gabapentin and pregabalin are prescription drugs that have been approved by the U.S. Food and Drug Administration. From 2011 to 2019, estimated annual gabapentin and pregabalin reports in NFLIS-Drug increased 242% and 18%, respectively. From 2019 to 2020, gabapentin and pregabalin reports decreased 7% and 28%, respectively.

Get the report.